3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis

European Journal of Medicinal Chemistry

Volumn 66, Issue , 2013, Pages 450-465

  Ferrins, Lori ^a   Rahmani, Raphaël ^a   Sykes, Melissa L ^b   Jones, Amy J ^b   Avery, Vicky M ^b   Teston, Eliott ^c   Almohaywi, Basmah ^d   Yin, JieXiang ^d,h   Smith, Jason ^d   Hyland, Chris ^d,h   White, Karen L ^a   Ryan, Eileen ^a   Campbell, Michael ^a   Charman, Susan A ^a   Kaiser, Marcel ^e,f   Baell, Jonathan B ^a,c,g  

^a MONASH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

3 (Oxazolo 4,5 b pyridin 2 yl)anilides; Human African trypanosomiasis; Sleeping sickness; Trypanosoma brucei; Trypanosomacidal agent

Indexed keywords

ANILIDE; ANTIPROTOZOAL AGENT; 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)ANILIDE DERIVATIVE; 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)ANILINE; 3 METHYL N [3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]FURAN 2 CARBOXAMIDE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; CHLOROQUINE; MELARSOPROL; MILTEFOSINE; N [3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]FURAN 2 CARBOXAMIDE; N [3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]FURAN 3 CARBOXAMIDE; N [3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]OXAZOLE 5 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYLBENZAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 1H IMIDAZOLE 3 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 1H PYRAZOLE 3 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 2 METHOXYACETAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 2 METHOXYBENZAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 3 METHOXYBENZAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] 3 METHYLFURAN 2 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL] PICOLINAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]BENZOFURAN 3 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]FURAN 2 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]FURAN 3 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]INICOTINAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]ISONICOTINAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]ISOZAXOLE 5 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]OZAXOLE 5 CARBOXAMIDE; N [4 CHLORO 3 (OXAZOLO[4,5 B]PYRIDIN 2 YL)PHENYL]THIAZOLE 4 CARBOXAMIDE; PODOPHYLLOTOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; NONHUMAN; PHYSICAL CHEMISTRY; TRYPANOSOMA BRUCEI; ANIMAL CELL; CARBON NUCLEAR MAGNETIC RESONANCE; HEK293 CELL LINE; MOUSE; PLASMODIUM FALCIPARUM; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; TRYPANOSOMA CRUZI; TRYPANOSOMA RHODESIENSE;

EID: 84879802453     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.05.007     Document Type: Article

References (41)

1. R. Brun, J. Blum, F. Chappuis, C. Burri, Human African trypanosomiasis, Lancet 375 (2010) 148-159.
2. WHO, Human African trypanosomiasis, http://www.who.int/trypanosomiasis- african/en/ (accessed 30.07.12).
3. WHO, Drugs, http://www.who.int/trypanosomiasis-african/drugs/en/index. html (accessed 27.07.12).
4. T.E. Voogd, E.L. Vansterkenburg, J. Wilting, L.H. Janssen, Recent research on the biological activity of suramin, Pharmacol. Rev. 45 (1993) 177-203. (Pubitemid 23191414)
5. H.P. de Koning, Transporters in African trypanosomes: role in drug action and resistance, Int. J. Parasitol. 31 (2001) 512-522.
6. A.J. Nok, Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis, Parasitol. Res. 90 (2003) 71-79. (Pubitemid 36577873)
7. T. Seebeck, P. Maser, Drug resistance in African trypanosomiasis, in: D.L. Mayers (Ed.), Antimicrobial Drug Resistance, Humana Press, 2009, pp. 589-604.
8. G. Priotto, S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. Pohlig, C. Schmid, U. Karunakara, E. Torreele, V. Kande, Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, noninferiority trial, Lancet 374 (2009) 56-64.
9. DNDi, Oxaborole SCYX-7158 (HAT), http://www.dndi.org/portfolio/oxaborole- scyx-7158.html (accessed 27.07.12).
10. DNDi, Pivotal study of fexinidazole for human African trypanosomiasis in stage 2, http://www.clinicaltrials.gov/ct2/show/NCT01685827?term= fexinidazole&rank=3#wrapper (accessed 23.11.12).
11. M.L. Sykes, J.B. Baell, M. Kaiser, E. Chatelain, S.R. Moawad, D. Ganame, J.-R. Ioset, V.M. Avery, Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS Campaign, PLoS Negl. Trop. Dis. 6 (2012) e1896.
12. L. Sanderson, M. Dogruel, J. Rodgers, B. Bradley, S.A. Thomas, The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain, J. Neurochem. 107 (2008) 1136-1146.
13. O. Balmer, J.S. Beadell, W. Gibson, A. Caccone, Phylogeography and taxonomy of Trypanosoma brucei, PLoS Negl Trop. Dis. 5 (2011).
14. H. Pajouhesh, G.R. Lenz, Medicinal chemical properties of successful central nervous system drugs, NeuroRx 2 (2005) 541-553. (Pubitemid 41393264)
15. J.-R. Ioset, Natural products for neglected diseases: a review, Curr. Org. Chem. 12, 643-666.
16. E. Torreele, B. Bourdin Trunz, D. Tweats, M. Kaiser, R. Brun, G. Mazué, M.A. Bray, B. Pécoul, Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness, PLoS Negl Trop. Dis. 4 (2010) e923.
17. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, K.R. Henne, A.E. Mutlib, D.K. Dalvie, J.S. Lee, Y. Nakai, J.P. O'Donnell, J. Boer, S.P. Harriman, A comprehensive listing of bioactivation pathways of organic functional groups, Curr. Drug Metab. 6 (2005) 161-225. (Pubitemid 40753853)
18. E. Handman, L. Kedzierski, A.D. Uboldi, J.W. Goding, Fishing for anti-leishmania drugs: principles and problems, Adv. Exp. Med. Biol. 625 (2008) 48-60.
19. J.E. Bemis, C.B. Vu, R. Xie, J.J. Nunes, P.Y. Ng, J.S. Disch, J.C. Milne, D.P. Carney, A.V. Lynch, L. Jin, J.J. Smith, S. Lavu, A. Iffland, M.R. Jirousek, R.B. Perni, Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators, Bioorg. Med. Chem. Lett. 19 (2009) 2350-2353.
20. T.M. Kowieski, S. Lee, J.M. Denu, Acetylation-dependent ADP-ribosylation by Trypanosoma brucei Sir2, J. Biol. Chem. 283 (2008) 5317-5326.
21. S. Alsford, T. Kawahara, C. Isamah, D. Horn, A sirtuin in the African trypanosome is involved in both DNA repair and telomeric gene silencing but is not required for antigenic variation, Mol. Microbiol. 63 (2007) 724-736. (Pubitemid 46105898)
22. M.-C. Viaud, P. Jamoneau, L. Savelon, G. Guillaumet, Synthesis of 6-Substituted 2-phenyloxazolo[4,5-b]pyridines, Heterocycles 41 (1995) 2799-2809.
23. P. Savarino, G. Viscardi, R. Carpignano, A. Borda, E. Barni, Aminophenyl-Xazolopyridines as precursors of heterocyclic azo dyes, J. Heterocycl. Chem. 26 (1989) 289-292.
24. C.D. Bevan, R.S. Lloyd, A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates, Anal. Chem. 72 (2000) 1781-1787. (Pubitemid 30220169)
25. F. Lombardo, M.Y. Shalaeva, K.A. Tupper, F. Gao, ElogDoct: a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds, J. Med. Chem. 44 (2001) 2490-2497. (Pubitemid 32852170)
26. K. Valko, S. Nunhuck, C. Bevan, M.H. Abraham, D.P. Reynolds, Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity, J. Pharm. Sci. 92 (2003) 2236-2248. (Pubitemid 37356697)
27. R.S. Obach, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metab. Dispos. 27 (1999) 1350-1359.
28. B. Davies, T. Morris, Physiological parameters in laboratory animals and humans, Pharm. Res. 10 (1993) 1093-1095. (Pubitemid 23211439)
29. R.E. Desjardins, C.J. Canfield, J.D. Haynes, J.D. Chulay, Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique, Antimicrob. Agents Chemother. 16 (1979) 710-718. (Pubitemid 10082023)
30. H. Matile, J.R.L. Pink, Plasmodium falciparum malaria parasite cultures and their use in immunology, in: I. Lefkovits, B. Pernis (Eds.), Immunological Methods, Academic Press, San Diego, 1990.
31. T. Ponnudurai, A.D. Leeuwenberg, J.H. Meuwissen, Chloroquine sensitivity of isolates of Plasmodium falciparum adapted to in vitro culture, Trop. Geogr. Med. 33 (1981) 50-54. (Pubitemid 11091208)
32. 50 in studies of drug resistance of malaria parasites, Acta Trop. 55 (1993) 257-261.
33. M.L. Cunningham, A.H. Fairlamb, Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials, Eur. J. Biochem. 230 (1995) 460-468.
34. J. Mikus, D. Steverding, A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue®, Parasitol. Int. 48 (2000) 265-269.
35. F.S. Buckner, C.L. Verlinde, A.C. La Famme, W.C. Van Voorhis, Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase, Antimicrob. Agents Chemother. 40 (1996) 2592-2597. (Pubitemid 26367650)
36. T. Baltz, D. Baltz, C. Giroud, J. Crockett, Cultivation in a semi-de fined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense, EMBO J. 4 (1985) 1273-1277.
37. B. Räz, M. Iten, Y. Grether-Bühler, R. Kaminsky, R. Brun, The Alamar Blue® assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro, Acta Trop. 68 (1997) 139-147. (Pubitemid 27438330)
38. B. Page, M. Page, C. Noel, A new fluorometric assay for cytotoxicity measurements in vitro, Int. J. Oncol. 3 (1993) 473-476. (Pubitemid 23271916)
39. S.A. Ahmed, R.M. Gogal, J.E. Walsh, A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay, J. Immunol. Methods 170 (1994) 211-224. (Pubitemid 24122510)
40. M.L. Sykes, V.M. Avery, Development of an Alamar Blue™ viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427, Am. J. Trop. Med. Hyg. 81 (2009) 665-674.
41. H. Hirumi, K. Hirumi, Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers, J. Parasitol. 75 (1989) 985-989. (Pubitemid 20099178)